Karo Pharma AB (STO:KARO), a drug research and development company, announced on Tuesday that Pfizer has informed the company about its decision to terminate the specific development project, PF-06763809. As a result, Karo Pharma will not receive further development and sales milestones related to the project.
In May 2018, Karo Pharma had communicated theoretical milestones of up to USD200m under this project.
The company added that in December 2011, it had entered into a research collaboration and license agreement with Pfizer (NYSE:PFE), with the purpose of discovering and developing substances that hamper the activity in the nuclear hormone receptor ROR-gamma, for treatment of autoimmune diseases.
After completion of the initial research collaboration, Pfizer has conducted the development work in -house, in accordance with the terms of the agreement, and has now terminated the project.
Karo Pharma clarified that the termination of this project has no impact on the running operations nor the business outlook.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial